### **Overview** Vijaya Diagnostic Centre Ltd. is India’s largest **B2C-focused, integrated diagnostics chain**, offering a comprehensive range of **pathology and radiology services under one roof**. Founded in **1981** in Hyderabad by Dr. S. Surendranath Reddy, the company has evolved into a national player with a dominant presence in South India and growing footprints in Western and Eastern India. Led by CEO Ms. Suprita Reddy, Vijaya emphasizes **patient-centric care, affordability, clinical excellence**, and **operational efficiency** through a scalable **hub-and-spoke model**. Operating over **160 diagnostic centers** and **25 reference laboratories** across **27 cities** in **Telangana, Andhra Pradesh, Karnataka, Maharashtra, West Bengal, and the NCR**, the company serves more than **4.3 million patients annually**, performing over **15 million tests**. --- ### **Business Model & Key Differentiators** - **Integrated Full-Stack Model**: Unique “**All Under One Roof**” model combining **pathology, radiology, cardiology**, and **nuclear diagnostics**, enhancing diagnostic accuracy, convenience, and speed. - **B2C Focus**: Over **95% of revenue** comes from direct consumer sales – significantly higher than peers – driving brand loyalty and pricing power. - **Hub-and-Spoke Expansion**: Central **hubs** (equipped with MRI, CT, automated labs) supported by lower-cost **spoke centers** for collection and basic imaging. This model enables efficient load-balancing, faster turnaround times (TAT), and profitability scaling. - **Technology-Driven Operations**: - AI-powered radiology platforms for faster reporting. - Digitized workflows via **LIMS, RIS, PACS**, and ERP systems. - Mobile app and website for end-to-end digital engagement (booking, payments, report access via WhatsApp). - **Home Collection Network**: Trained phlebotomists with **temperature-controlled logistics** ensure sample integrity and reach labs within **2 hours**. --- ### **Strategic Expansion & Market Penetration (FY25–FY26)** #### **1. Geographic Expansion** - **Core Markets (AP & Telangana)**: Remains the bedrock, with strong brand recall and dense network. Key upgrades in **Kurnool** (3T MRI, 160-slice CT) and new hubs in **Nizamabad (Nov 2024)** and **Ongole (Aug 2024)**. - **Western India (Pune)**: Entry via acquisition of **PH Diagnostic Centre (Dec 2023)**, Pune’s largest B2C diagnostic chain. PH’s 18 centers integrated and rebranded as **‘Vijaya PH Diagnostic Centre’**. Flagship hub launched in **Ambegaon (Apr 2025)** with back-end functions (IT, call center, central stores). - **Eastern India (Kolkata & West Bengal)**: - Launched centers on **VIP Road** and **Barasat**. - Plans for **6+ hubs** by mid-FY26, including **Kasba (Q2 FY26)**, featuring the **region’s first 3T MRI**. - **Karnataka (Bengaluru)**: **Organic entry in FY26** with hubs in **HSR Layout (Apr 2025)** and **Yelahanka (Jul 2025)**. Strategic testing of replication potential in this competitive market. - **Tier 2/3 Cities Focus**: Major growth engine via expansion into **Nandyal, Khammam, Ongole, Nizamabad**, and **Tirupati**. Facilities here offer **high-end imaging (e.g., 3T MRI)** rare in non-metro areas. #### **2. FY26 Expansion Plan** - **Launch of 10–11 new hub centers** in **Bengaluru (2), Pune (5), and West Bengal (3–4)**. - Investments funded through **internal accruals** and **cash reserves (~INR 200 crores surplus)**. - Target: **Rs. 50–100 crore revenue** from Eastern India within **2–3 years**. - Average **break-even in 6–9 months** for new hubs; most centers become profitable within two quarters. --- ### **Inorganic Growth & Strategic Acquisitions** - **PH Diagnostic Centre Acquisition (Dec 2023, ₹147.5 Cr)**: - 18 centers (3 hubs, 3 spokes, 12 collection). - Added **~₹45 crore in annual revenue**. - Strengthened B2C footprint in **Pune** and enhanced **wellness segment (12–14% of revenue)**. - Post-acquisition integration complete; **legacy B2B clients discontinued** due to payment issues. - **Medinova Diagnostic Services Limited – Merger Pending**: - Stock exchange approvals secured (Jul 2025). - Share exchange ratio: **1 Vijaya share for 22 Medinova shares**. - Expected to improve **backend capacity, operational synergies**, and strengthen eastern India presence. --- ### **Technology & Operational Excellence** - **Imaging Infrastructure**: - **34 MRI**, **34 CT**, and **9 PET CT/Gamma Camera** units. - 3T MRI installed in **Tirupati, Kolkata, Ambegaon, HSR Layout, Nizamabad, and Nandyal**. - **Digital Enablement**: - AI-powered radiology software by global vendors enables **secure WhatsApp report sharing, centralized case routing**, and **3-hour TAT for MRI epilepsy protocols**. - **Web-based LIMS and RIS** reduced routine test TAT to **≤6 hours**. - **Quality & Compliance**: - **17 NABL-accredited labs**; **NABH-certified centers**. - Standardized SOPs, in-house medical team, and **tele-radiology network** of **300+ radiologists and pathologists**. --- ### **Financial & Operational Performance (FY25 Highlights)** | Metric | FY25 Performance | |-------|------------------| | **Patient Footfalls** | ~4.33 million | | **Tests Conducted** | ~15.36 million | | **Revenue Mix** | 64% pathology, 36% radiology | | **Wellness Revenue** | 12–14% (up from 8–9% pre-COVID) | | **Corporate Client Revenue** | ~7% (annual health check-ups) | | **EBITDA Margin** | Consistently above **40%** | | **Network Size** | 160+ centers, 25 RLs, 27 cities | | **Growth Drivers** | Double-digit growth in existing centers + **strong new hub performance** |